DAVOS, Switzerland, Jan 27 (Reuters) - A proxy battle for control of Genzyme (GENZ.O) is unlikely, given the progress being made in discussions with Sanofi-Aventis (SASY.PA), the U.S. biotech group’s chief executive said on Thursday.
DAVOS, Switzerland, Jan 27 (Reuters) - A proxy battle for control of Genzyme (GENZ.O) is unlikely, given the progress being made in discussions with Sanofi-Aventis (SASY.PA), the U.S. biotech group’s chief executive said on Thursday.
